Solitary Pulmonary Nodule Clinical Trial
Official title:
Multi Center Clinical Study of Three Plus Two Type Early Diagnosis of Pulmonary Nodules in Medical Internet of Things
Medical The Internet of Things (IoT), a recent breakthrough in communication technology, could be helpful in improving health care delivery and saving medical costs, but regarding pulmonary nodule management it is still at the basic understanding. Investigators adopt "Internet of things medical three plus two type pulmonary nodule diagnosis" which chun-xue Bai put forward, used a developed a mobile phone-based IoT (mIoT) platform and initiated a randomized, multicenter, controlled trial to value clinical effectivity of "Internet of things medical three plus two type pulmonary nodule diagnosis" in the management of pulmonary nodules. In this study, at least 600 patients with pulmonary nodules (no typical symptoms, often single, clear boundary, increased density, soft tissue shadow surrounded by lung parenchyma with diameter ≤3 cm) will be randomly allocated to the control group, which receives routine follow-up, or the intervention group, which receives "Internet of things medical three plus two type pulmonary nodule diagnosis" management. Endpoints of the study include: (1) The positive diagnosis rate of lung cancer in I stage; (2) 5 year disease-free survival rate and overall survival rate; (3) direct medical costs per year. Results from this study should provide direct evidence for the suitability of "Internet of things medical three plus two type pulmonary nodule diagnosis" in pulmonary nodules patients management.
Status | Recruiting |
Enrollment | 600 |
Est. completion date | August 2020 |
Est. primary completion date | August 2020 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Subjects must meet the following criteria: Inclusion Criteria: 1. Over 18 years old; 2. Single or multiple round solitary pulmonary nodules surrounded by lung parenchyma without associated atelectasis, diameter < 3 cm of small pulmonary nodules; 3. Patients should be capable of reading and writing Chinese, without impaired verbal communication; 4. Patients should be capable of using intellectual equipment. Exclusion criteria: 1. Chest CT present lung mass, large seepage or atelectasis; 2. Other active chronic respiratory system diseases needing be diagnosed , intervention and treatment; 3. Severe or uncontrolled complications of other systems; 4. Complicated with pleural effusion; 5. Patients with cognitive impairment or mental abnormalities being unable to complete the questionnaire. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
China | XZhang | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Henan Provincial Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The positive diagnosis rate of lung cancer in I stage | 5 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05066776 -
Liquid Biopsy With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules
|
||
Completed |
NCT01958931 -
Evaluate the Utility of the ProLung Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer
|
N/A | |
Recruiting |
NCT03528733 -
Feasibility of Multi-Energy Digital Radiography Detector for Lung Lesions Detection
|
N/A | |
Recruiting |
NCT02693496 -
Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research
|
||
Completed |
NCT01566682 -
A Multi-Center Trial of the ProLung Test™
|
||
Terminated |
NCT02983903 -
Cryobiopsy Versus Forceps Biopsy for Pulmonary Lesions
|
N/A | |
Terminated |
NCT02050724 -
ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT
|
Phase 2 | |
Not yet recruiting |
NCT04615156 -
18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography
|
Phase 3 | |
Recruiting |
NCT02726633 -
Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer
|
N/A | |
Active, not recruiting |
NCT02623712 -
The Watch the Spot Trial
|
N/A | |
Recruiting |
NCT03568799 -
4-[18F]Fluoroglutamine PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
|
N/A | |
Not yet recruiting |
NCT02817048 -
Tubeless VATS for Peripheral Lung Nodule
|
N/A | |
Recruiting |
NCT01149187 -
Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules
|
N/A | |
Completed |
NCT00925210 -
Bronchoscopic Approach to the Peripheral Lung Nodule - An Alternative Approach
|
Phase 2 | |
Completed |
NCT02448225 -
18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
|
Phase 2 | |
Active, not recruiting |
NCT05171491 -
LungLB in Subjects Presenting With Indeterminate Pulmonary Nodules
|
||
Terminated |
NCT04140474 -
Evaluation of the Archimedes ™ System for Transparenchymatous Access to Pulmonary Nodules.
|
N/A | |
Withdrawn |
NCT05804435 -
iNod™ Ultrasound-Guided Needle Biopsy System Study
|
N/A | |
Not yet recruiting |
NCT02653859 -
Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells in Benign and Malignant Lung Nodules
|
N/A | |
Completed |
NCT02832284 -
iNod System Human Feasibility Assessment
|
N/A |